No profile data available.
Aspen Pharmacare Holdings Limited (APNHY) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Durban, South Africa.
It reported revenue of 43.36 billion ZAR for fiscal year 2025, down 3.0% from fiscal year 2024, and net income of -1.08 billion ZAR. Its largest business segment, Commercial Pharmaceuticals - Prescription, brought in 29% of segment revenue in fiscal year 2025; Europe CIS was the largest region with 34%. Its market capitalization was $4.09 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2025; market data as of October 9, 2026.
Aspen Pharmacare Holdings Limited, together with its subsidiaries, operates as a specialty and branded pharmaceutical company in Africa, the Middle East, Europe, CIS, Australasia, Asia, and the Americas. It operates through Commercial Pharmaceuticals and Manufacturing segments.
Aspen Pharmacare Holdings reported 43.36 billion ZAR in revenue for fiscal year 2025, down 3.0% from 44.71 billion ZAR in fiscal year 2024.
Commercial Pharmaceuticals - Prescription, with 12.52 billion ZAR or 29% of segment revenue in fiscal year 2025. Next: Manufacturing (26%) and Commercial Pharmaceuticals - Injectables (23%).
Europe CIS: 34% of revenue by region in fiscal year 2025, followed by Africa Middle East (24%).
$4.09 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Crispr Therapeutics AG (CRSP), Grifols, S.a. (GRFS), Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (GEDSF), CMS (CHSYF).